A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Unresectable Pancreatic Cancer
Interventions
DEVICE

Suizenji

HIFU treatment

DRUG

Nal-IRI/FL

Nanoliposomal irinotecan, Fluorouracil, Levofolinate

DRUG

mFOLFIRINOX

Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin

DRUG

Gem/nab-PTX

Gemcitabine, nab-Paclitaxel

Trial Locations (7)

480-1195

RECRUITING

Aichi Medical University Hospital, Nagakute-shi, Aichi

980-8574

RECRUITING

Tohoku University Hospital, Sendai-shi, Miyagi

160-0023

RECRUITING

Tokyo Medical University Hospita, Shinjuku-ku, Tokyo

930-0194

RECRUITING

Toyama University Hospital, Toyama-shi, Toyama

641-8510

RECRUITING

Wakayama Medical University Hospital, Wakayama-shi, Wakayama

232-0024

RECRUITING

Yokohama City University Medical Center, Yokohama-shi, Kanagawa

241-8515

RECRUITING

Kanagawa Cancer Center, Yokohama-shi, Kanagawa

All Listed Sponsors
lead

SONIRE Therapeutics Inc.

INDUSTRY